Dr. Grupp on Optimal Treatment Settings for CAR-Modified T Cells

Video

Stephan Grupp, MD, PhD, of the Children's Hospital of Philadelphia, discusses the optimal treatment settings for novel CD19-specific CAR-modified T cell therapies in patients with acute lymphoblastic leukemia.

Stephan Grupp, MD, PhD, of the Children’s Hospital of Philadelphia, discusses the optimal treatment settings for novel CD19-specific CAR-modified T cell therapies in patients with acute lymphoblastic leukemia (ALL).

CAR-modified T cell therapies have generated excitement, as novel treatments for patients with ALL. In updated findings from 39 pediatric patients with relapsed/refractory ALL, the complete remission rate was 92%. In this population, this is a good treatment option, Grupp notes.

Given the high-level of efficacy seen with upfront chemotherapy in pediatric patients, Grupp believes the CAR T cell therapies are best suited for later lines of treatment. However, in adult patients with ALL, approximately half of patients progress on frontline therapy. For this population, CAR T cell therapies could be beneficial in earlier settings. At this point, Grupp remains uncertain whether the novel immunotherapies could ever replace frontline chemotherapy in ALL.

<<<

View more from the 2014 ASH Annual Meeting

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine
Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford
© 2025 MJH Life Sciences

All rights reserved.